Analyst Price Targets — CODX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 14, 2022 6:26 am | — | H.C. Wainwright | $180.00 | $109.50 | Benzinga | HC Wainwright & Co. Maintains Buy on Co-Diagnostics, Lowers Price Target to $6 |
| August 15, 2022 6:19 am | — | H.C. Wainwright | $270.00 | $134.40 | Benzinga | HC Wainwright & Co. Maintains Buy on Co-Diagnostics, Lowers Price Target to $9 |
| May 16, 2022 6:59 am | — | H.C. Wainwright | $360.00 | $136.50 | Benzinga | HC Wainwright & Co. Maintains Buy on Co-Diagnostics, Lowers Price Target to $12 |
Latest News for CODX
SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of Wes Lindsey, PhD, MBA as the Company's new Chief Scientific Officer ("CSO"). Dr. Lindsey brings more than 20 years' experience in molecular diagnostics.
Invited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partner Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of WHO-recommended near-point-of-care diagnostics SALT LAKE CITY, July 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics…
More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs Analytical data to support concurrent 510(k) submission with CLIA Waiver by Application for point-of-care settings, with submission targeted for Q3 2026 SALT LAKE CITY, July 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a…
Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week SALT LAKE CITY, June 25, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its mosquito abatement…
Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro ® and expanding menu of molecular diagnostics products across a key Latin American market SALT LAKE CITY, June 11, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CODX.
U.S. House Trading
No House trades found for CODX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.